Oppenheimer’s Derek Archila says Teva shares are “not cheap” considering the risk factor of the new cost-cutting plan and headwinds circling.
GBH Insights’ analyst Daniel Ives weighs in on Amazon’s next big move: the expansion of its “consumer empire” with a second headquarters.
In the foreseeable future, Maxim’s Jason Kolbert finds it unlikely TEVA will find itself in a place to boost its guidance.
Ahead of the fourth quarter showcase from Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) anticipated March 7th, first …
RBC Capital’s Joseph Spak pinpoints 21% upside potential for General Motors stock, betting GM International is nearing breakeven by 2019.
Rosenblatt’s Jun Zhang says he looks for iPhone X cuts in the first fiscal quarter to circle 3 million- not the massive 10 million bears are expecting.
RBC’s Joseph Spak cuts his estimates on Tesla following 4Q17 production/delivery results and on the heels of last week’s Detroit Auto Show.